Project Grant K76AG095107
- This $412,751 Project Grant, awarded on August 15, 2024 by the National Institute on Aging (CFDA 93.866 - Aging Research), will fund research by The Trustees of Columbia University in the City of New York to study protein turnover alterations in the aging brain. The project aims to: (I) study the stoichiometry of the ribosome and proteasome; (II) measure changes in protein complex composition; (III) reveal how aging affects protein interaction state turnover; and (IV) address the effects of...
- This $15,046,454 project grant from the National Institutes of Health National Institute on Aging, under the Aging Research program (CFDA 93.866), will fund research at the University of California, San Diego to improve understanding of proteomic changes preceding Alzheimer's disease and related dementias. The research will analyze longitudinal plasma samples from 2,836 women in the Women's Health Initiative Memory Study cohort using the Somamscan proteomics platform to identify novel...
- This Project Grant award of $437,875 from the National Institute on Aging's Aging Research program (CFDA 93.866) will fund a 2-year research project at the University of California, San Diego to quantify neurovascular protein lifetimes in the central nervous system under healthy, aging, and Alzheimer's disease conditions. The key objectives are to generate a comprehensive atlas of neurovascular protein lifetimes and identify changes associated with aging and Alzheimer's disease. The project will...
- This Project Grant award from the National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), aims to identify multi-scale mechanisms contributing to age-related increases in the metabolic cost of walking and decreases in walking speed. The $3,224,215 award to Georgia Tech Research Corp, to be completed by July 31, 2029, will leverage a multi-scale, computational-experimental approach to probe the cellular-to-behavioral mechanisms linking the...
- This $326,797 Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) aims to identify proteomic (protein-based) biomarkers that can predict risk of cognitive impairment in individuals with type 2 diabetes. The primary goal is to use proteomic analyses to discover plasma protein differences and networks associated with newly diagnosed mild cognitive impairment in this population. The project will also examine how these proteins relate to preclinical...
- This Project Grant award of $673,012 from the National Institute on Aging (CFDA 93.866 - Aging Research) will support research to understand the neuromechanical bases for the increased energy cost of walking in aging. The University of Massachusetts is the primary awardee, with the goal of determining how age-related changes in gait strategy combine with muscle weaknesses to increase the energy cost of walking in older adults. The research will address key knowledge gaps regarding relative...
- This federal Project Grant award of $1,574,743.00 was provided by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866) to Vanderbilt University Medical Center (VUMC) to study the effects of serum psychotropic drug levels and drug metabolizer status on delirium duration and long-term cognition in older hospitalized patients. The research aims to identify new targets for deprescribing psychotropic medications, such as selective serotonin and...
- This Project Grant award of $1,631,690.00 from the National Institute on Aging (CFDA 93.866 - Aging Research) to Beth Israel Deaconess Medical Center, Inc. (Bidmc) supports a research project titled "Proteomic Signatures of Delirium and Long-Term Cognitive Decline in Older Cardiac Surgical Patients." The project aims to use state-of-the-art proteomics analysis to derive and validate a delirium protein signature for cardiac surgery patients, leveraging plasma samples from an ongoing...
- The National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), awarded a $478,624 Project Grant to President and Fellows of Harvard College (Harvard Medical School) to develop cross-platform fluorescent reporters for measuring the activities of the 26S proteasome and VCP/p97 complexes. These master regulators broadly control ubiquitin-dependent protein breakdown, which is closely associated with aging and age-related pathologies such as Alzheimer's disease...
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to Rutgers, The State University of New Jersey aims to elucidate the role of the glycoproteome in Alzheimer's disease and related dementias (AD/ADRD). The $795,436 award, beginning April 1, 2025, will identify novel glycopeptiforms related to AD/ADRD pathologies and clinical traits, test if glycopeptiforms link an active lifestyle with brain health, and characterize the genetic architecture of...
This Project Grant award of $242,489.00 from the National Institute on Aging (part of the U.S. Department of Health and Human Services) under the Aging Research federal grant program (CFDA 93.866) will fund research by Vanderbilt University Medical Center to investigate the proteomic signature associated with the dual decline of both gait and cognition in older adults. The study aims to leverage a deeply phenotyped research cohort and state-of-the-art plasma proteomics techniques to determine the unique proteomic profile linked to the combined decline in gait and cognitive function - a condition that significantly increases the risk of developing dementia. The research will use both cross-sectional and longitudinal analysis methods to advance the understanding of the underlying pathophysiological changes that connect deteriorating gait and cognitive impairment. This knowledge could inform earlier detection and interventions for this high-risk dual decline population.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $242.5k | 9/2/25 |